Back to top
more

Pediatrix Medical Group, Inc. (MD)

(Real Time Quote from BATS)

$11.10 USD

11.10
125,944

+0.08 (0.73%)

Updated Aug 29, 2024 02:06 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 33% (168 out of 251)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

MD or RVTY: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

MD vs. RVTY: Which Stock Is the Better Value Option?

All You Need to Know About Pediatrix Medical Group (MD) Rating Upgrade to Strong Buy

by Zacks Equity Research

Pediatrix Medical Group (MD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Here Is Why Bargain Hunters Would Love Fast-paced Mover Pediatrix Medical Group (MD)

by Zacks Equity Research

If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Pediatrix Medical Group (MD) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.

MD or RVTY: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

MD vs. RVTY: Which Stock Is the Better Value Option?

Pediatrix (MD) Q2 Earnings Top on Stable Volumes, Shares Up 7.4%

by Zacks Equity Research

Pediatrix's (MD) second-quarter earnings benefit from stable patient volumes. Rising expenses act as a partial offset.

Pediatrix Medical Group (MD) Q2 Earnings Surpass Estimates

by Zacks Equity Research

Pediatrix Medical Group (MD) delivered earnings and revenue surprises of 9.68% and 0.24%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Implied Volatility Surging for Pediatrix Medical (MD) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Pediatrix Medical (MD) stock based on the movements in the options market lately.

Implied Volatility Surging for Pediatrix Medical (MD) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Pediatrix Medical (MD) stock based on the movements in the options market lately.

Why Is Pediatrix Medical Group (MD) Down 15.9% Since Last Earnings Report?

by Zacks Equity Research

Pediatrix Medical Group (MD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Pediatrix (MD) Q1 Earnings Beat on Hospital Contract Fees

by Zacks Equity Research

Pediatrix's (MD) Q1 results benefit from higher same-unit revenues, resulting from growing patient volumes, partly offset by high costs. It continues to expect 2024 adjusted EBITDA within $200-$220 million.

Compared to Estimates, Pediatrix Medical Group (MD) Q1 Earnings: A Look at Key Metrics

by Zacks Equity Research

The headline numbers for Pediatrix Medical Group (MD) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Life Time Group Holdings, Inc. (LTH) Q1 Earnings Miss Estimates

by Zacks Equity Research

Life Time Group Holdings (LTH) delivered earnings and revenue surprises of -6.25% and 1.39%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

ICON (ICLR) Up 7.6% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

ICON (ICLR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Pediatrix Medical Group, Inc. (MD) Up 11% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Pediatrix Medical Group, Inc. (MD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Pediatrix's (MD) Q4 Earnings Miss Due to Soft Patient Volumes

by Zacks Equity Research

Pediatrix's (MD) Q4 results were hit by an increase in overall cost level resulting from higher same-unit clinical compensation costs. Yet, an impressive 2024 adjusted EBITDA guidance is likely to provide relief to investors.

Pediatrix Medical Group (MD) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates

by Zacks Equity Research

Although the revenue and EPS for Pediatrix Medical Group (MD) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Will High Expenses Ail Pediatrix Medical's (MD) Q4 Earnings?

by Zacks Equity Research

Pediatrix Medical's (MD) Q4 results are likely to be hurt by an increase in practice salaries and benefits expense as well as softer patient volumes, partly offset by same-unit pricing growth.

Pediatrix (MD) Q3 Earnings Miss on High Costs, Shares Down 12%

by Zacks Equity Research

Pediatrix's (MD) third-quarter results suffer from the decline in same-unit revenues attributable to patient volume. Management currently expects 2023 adjusted EBITDA to be within $200-$210 million.

Pediatrix Medical Group (MD) Lags Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Pediatrix Medical Group (MD) delivered earnings and revenue surprises of -25.58% and 0.43%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Establishment Labs Holdings Inc. (ESTA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Establishment Labs Holdings Inc. (ESTA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Revvity (RVTY) Misses Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Revvity (RVTY) delivered earnings and revenue surprises of -0.84% and 3.10%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Pediatrix Medical Group (MD) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Pediatrix Medical Group (MD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

MD or DOCS: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

MD vs. DOCS: Which Stock Is the Better Value Option?

Why Investors Are Retaining Pediatrix Medical (MD) Stock Now

by Zacks Equity Research

Pediatrix Medical's (MD) rising net patient service revenues will likely benefit its top line.

Pediatrix Medical Group (MD) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

The headline numbers for Pediatrix Medical Group (MD) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.